KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $73.0 million.

  • Moderna's Other Accumulated Expenses rose 579.71% to $73.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.0 million, marking a year-over-year increase of 579.71%. This contributed to the annual value of $221.0 million for FY2024, which is 7131.78% up from last year.
  • As of Q3 2025, Moderna's Other Accumulated Expenses stood at $73.0 million, which was up 579.71% from $192.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Other Accumulated Expenses ranged from a high of $613.0 million in Q2 2021 and a low of $42.0 million during Q2 2024
  • For the 5-year period, Moderna's Other Accumulated Expenses averaged around $239.2 million, with its median value being $225.0 million (2021).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 721329.04% in 2021, then crashed by 8220.34% in 2024.
  • Over the past 5 years, Moderna's Other Accumulated Expenses (Quarter) stood at $225.0 million in 2021, then grew by 10.67% to $249.0 million in 2022, then tumbled by 48.19% to $129.0 million in 2023, then soared by 71.32% to $221.0 million in 2024, then tumbled by 66.97% to $73.0 million in 2025.
  • Its Other Accumulated Expenses was $73.0 million in Q3 2025, compared to $192.0 million in Q2 2025 and $252.0 million in Q1 2025.